Drugs / SYS6002
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07241936 | Nov 2025 → Oct 2027 expected | cancer | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06989671 | Aug 2025 → Dec 2027 expected | head and neck squamous cell carcinoma | CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07526792 | Jun 2026 → Jun 2029 expected | urothelial carcinoma | CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07230626 | Nov 2025 → Jan 2028 expected | cervical cancer | CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07374549 Comparator | Jun 2026 → Jun 2028 expected | urothelial carcinoma | CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYS6002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06989671 ↗ |
| Modality | Other / unclassified | “anti-nectin-4 ADC” NCT06989671 ↗ |
| Route | Intravenous | “SYS6002 Q2W or Q3W, intravenous injection” NCT06989671 ↗ |